The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Jonathan W. Friedberg, Julie Marie Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick Peterson, Lynn Rich, Susan Blumel, Nicole K. Proia, Jane Liesveld, Richard I. Fisher, James Olen Armitage, Steven Grant, John P. Leonard

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were treated with bendamustine 90 mg/m2 days 1 and 4; rituximab 375 mg/m2 day 1, and bortezomib 1.3 mg/m 2 days 1, 4, 8, 11. Six 28-day cycles were planned. Thirty patients (7 with mantle cell lymphoma) were enrolled and treated. Eight patients experienced serious adverse events, including one event of grade 5 sepsis. Common nonhematologic adverse events were generally grade 1 or grade 2 and included nausea (50%), neuropathy (47%), fatigue (47%), constipation (40%), and fever (40%). Of 29 patients evaluable for efficacy, 24 (83%) achieved an objective response (including 15 with complete response). With median follow-up of 24 months, 2-year progression-free survival is 47% (95% confidence interval, 25%-69%). On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534.

Original languageEnglish (US)
Pages (from-to)2807-2812
Number of pages6
JournalBlood
Volume117
Issue number10
DOIs
StatePublished - Mar 10 2011

Fingerprint

Mantle-Cell Lymphoma
Refractory materials
Non-Hodgkin's Lymphoma
Fatigue of materials
Constipation
Nausea
Disease-Free Survival
Fatigue
Sepsis
Fever
Bortezomib
Bendamustine Hydrochloride
Rituximab
Confidence Intervals

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. / Friedberg, Jonathan W.; Vose, Julie Marie; Kelly, Jennifer L.; Young, Faith; Bernstein, Steven H.; Peterson, Derick; Rich, Lynn; Blumel, Susan; Proia, Nicole K.; Liesveld, Jane; Fisher, Richard I.; Armitage, James Olen; Grant, Steven; Leonard, John P.

In: Blood, Vol. 117, No. 10, 10.03.2011, p. 2807-2812.

Research output: Contribution to journalArticle

Friedberg, JW, Vose, JM, Kelly, JL, Young, F, Bernstein, SH, Peterson, D, Rich, L, Blumel, S, Proia, NK, Liesveld, J, Fisher, RI, Armitage, JO, Grant, S & Leonard, JP 2011, 'The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma', Blood, vol. 117, no. 10, pp. 2807-2812. https://doi.org/10.1182/blood-2010-11-314708
Friedberg, Jonathan W. ; Vose, Julie Marie ; Kelly, Jennifer L. ; Young, Faith ; Bernstein, Steven H. ; Peterson, Derick ; Rich, Lynn ; Blumel, Susan ; Proia, Nicole K. ; Liesveld, Jane ; Fisher, Richard I. ; Armitage, James Olen ; Grant, Steven ; Leonard, John P. / The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. In: Blood. 2011 ; Vol. 117, No. 10. pp. 2807-2812.
@article{3289186e82944d37a69a825cef074f14,
title = "The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma",
abstract = "Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were treated with bendamustine 90 mg/m2 days 1 and 4; rituximab 375 mg/m2 day 1, and bortezomib 1.3 mg/m 2 days 1, 4, 8, 11. Six 28-day cycles were planned. Thirty patients (7 with mantle cell lymphoma) were enrolled and treated. Eight patients experienced serious adverse events, including one event of grade 5 sepsis. Common nonhematologic adverse events were generally grade 1 or grade 2 and included nausea (50{\%}), neuropathy (47{\%}), fatigue (47{\%}), constipation (40{\%}), and fever (40{\%}). Of 29 patients evaluable for efficacy, 24 (83{\%}) achieved an objective response (including 15 with complete response). With median follow-up of 24 months, 2-year progression-free survival is 47{\%} (95{\%} confidence interval, 25{\%}-69{\%}). On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534.",
author = "Friedberg, {Jonathan W.} and Vose, {Julie Marie} and Kelly, {Jennifer L.} and Faith Young and Bernstein, {Steven H.} and Derick Peterson and Lynn Rich and Susan Blumel and Proia, {Nicole K.} and Jane Liesveld and Fisher, {Richard I.} and Armitage, {James Olen} and Steven Grant and Leonard, {John P.}",
year = "2011",
month = "3",
day = "10",
doi = "10.1182/blood-2010-11-314708",
language = "English (US)",
volume = "117",
pages = "2807--2812",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

AU - Friedberg, Jonathan W.

AU - Vose, Julie Marie

AU - Kelly, Jennifer L.

AU - Young, Faith

AU - Bernstein, Steven H.

AU - Peterson, Derick

AU - Rich, Lynn

AU - Blumel, Susan

AU - Proia, Nicole K.

AU - Liesveld, Jane

AU - Fisher, Richard I.

AU - Armitage, James Olen

AU - Grant, Steven

AU - Leonard, John P.

PY - 2011/3/10

Y1 - 2011/3/10

N2 - Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were treated with bendamustine 90 mg/m2 days 1 and 4; rituximab 375 mg/m2 day 1, and bortezomib 1.3 mg/m 2 days 1, 4, 8, 11. Six 28-day cycles were planned. Thirty patients (7 with mantle cell lymphoma) were enrolled and treated. Eight patients experienced serious adverse events, including one event of grade 5 sepsis. Common nonhematologic adverse events were generally grade 1 or grade 2 and included nausea (50%), neuropathy (47%), fatigue (47%), constipation (40%), and fever (40%). Of 29 patients evaluable for efficacy, 24 (83%) achieved an objective response (including 15 with complete response). With median follow-up of 24 months, 2-year progression-free survival is 47% (95% confidence interval, 25%-69%). On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534.

AB - Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were treated with bendamustine 90 mg/m2 days 1 and 4; rituximab 375 mg/m2 day 1, and bortezomib 1.3 mg/m 2 days 1, 4, 8, 11. Six 28-day cycles were planned. Thirty patients (7 with mantle cell lymphoma) were enrolled and treated. Eight patients experienced serious adverse events, including one event of grade 5 sepsis. Common nonhematologic adverse events were generally grade 1 or grade 2 and included nausea (50%), neuropathy (47%), fatigue (47%), constipation (40%), and fever (40%). Of 29 patients evaluable for efficacy, 24 (83%) achieved an objective response (including 15 with complete response). With median follow-up of 24 months, 2-year progression-free survival is 47% (95% confidence interval, 25%-69%). On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534.

UR - http://www.scopus.com/inward/record.url?scp=79953077610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953077610&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-11-314708

DO - 10.1182/blood-2010-11-314708

M3 - Article

C2 - 21239695

AN - SCOPUS:79953077610

VL - 117

SP - 2807

EP - 2812

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -